(R)-Bromoenol lactone-d7
CAT:
804-HY-117068S
Size:
Inquire
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No

(R)-Bromoenol lactone-d7
- UNSPSC Description: (R)-Bromoenol lactone-d7 ((R,E)-Bromoenol lactone-d7) is deuterium labeled (R)-Bromoenol lactone. (R)-Bromoenol lactone ((R)-BEL) is an irreversible, chiral, mechanism-based inhibitor of calcium-independent phospholipase γ (iPLA2γ). (R)-BEL inhibits human recombinant iPLA2γ with an IC50 of approximately 0.6 μM[1][2].
- Target Antigen: Isotope-Labeled Compounds; Phospholipase
- Type: Isotope-Labeled Compounds
- Related Pathways: Metabolic Enzyme/Protease;Others
- Field of Research: Others
- Smiles: [2H]C1=C(C([2H])=C2C(C([2H])=C(C([2H])=C2[C@@]3(C(O/C(CC3)=C/Br)=O)[H])[2H])=C1[2H])[2H]
- Molecular Weight: 324.22
- References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Jenkins CM, et al. Identification of calcium-independent phospholipase A2 (iPLA2) beta, and not iPLA2gamma, as the mediator of arginine vasopressin-induced arachidonic acid release in A-10 smooth muscle cells. Enantioselective mechanism-based discrimination of mammalian iPLA2s. J Biol Chem. 2002 Sep 6;277(36):32807-14.
- Shipping Conditions: Room temperature
- Clinical Information: Phase 1